involve the use of viable somatic cells for therapeutic purposes.

Tissue-engineered Products (TEPs): These products include engineered tissues or cells that are intended to repair, regenerate, or replace human tissues.

The regulatory framework for ATMPs is primarily defined under Regulation (EC) No 1394/2007. It is important to discern that ATMPs can also fall under borderline products, which may require a nuanced assessment to determine the applicable regulatory pathway. These products often challenge traditional classifications due to their complex nature and the combination of medicinal and therapeutic principles.

This step sets the foundation for understanding the roles of various stakeholders including regulatory agencies, manufacturers, researchers, and healthcare providers. Gaining an understanding of the EMA’s Comprehensive Assessment Team (CAT) is crucial, as they play a vital role in the evaluation of ATMPs, especially those posing significant innovation challenges. Familiarizing oneself with the EMA website can provide the latest updates and insights relevant to ATMP assessment procedures.

Step 2: Preparing the ATMP Dossier

A critical component of the regulatory approval process for ATMPs is the preparation of the scientific dossier, which must comply with the EMA’s regulatory submission requirements. The Common Technical Document (CTD) serves as the framework for data compilation, and regulatory teams should focus on gathering comprehensive documentation under the following headings:

• Module 1 – Administrative Information: This includes application forms, product information, and labeling materials.
• Module 2 – Quality Overall Summary: A concise summary of quality data from Module 3.
• Module 3 – Quality: Data related to the product’s pharmaceutical development, manufacturing processes, quality controls, and stability.
• Module 4 – Non-clinical Study Reports: Reports detailing the results of animal studies to assess the safety and efficacy of the ATMP.
• Module 5 – Clinical Study Reports: Summaries of clinical trials that evaluate the safety and efficacy of the ATMP.

Documentation expectations for the quality section of the dossier (Module 3) are particularly stringent, requiring detailed information on raw materials, manufacturing processes, and quality controls. Specific attention should be given to compliance with Good Manufacturing Practice (GMP) as outlined in GMP guidelines to ensure that the product is consistent, compliant, and of high quality.

Clinical data must demonstrate a favorable risk-benefit profile. It’s essential to define the target patient population, endpoints, and methodologies for the clinical trials accurately. Documentation related to informed consent processes, the ethical approval of the study, and adherence to ICH-GCP guidelines are also scrutinized rigorously.

The process of compiling this dossier is iterative and may require multiple revisions based on internal reviews and discussions with regulatory consultants and advisors. This is particularly important for ATMPs, which may involve frequently evolving science and technology.

Step 3: Engagement with Regulatory Authorities

Engaging with regulatory authorities early in the development process is strategic in defining clear expectations and addressing potential challenges upfront. This can include pre-submission meetings or consultations that provide insights into regulatory requirements, data sufficiency, and potential approval pathways.

The EMA offers Protocol Assistance for ATMPs to help developers understand the scientific and regulatory requirements early. Participation in these consultations can facilitate discussions about the product development plan, clinical trial design, and necessary documentation. These interactions can guide developers in making pivotal decisions about study designs and regulatory pathways.

Moving forward, regulatory authorities in the US, such as the FDA, have established frameworks that differ from the EMA regarding the classification of gene therapy and somatic cell products. Understanding the HCT/P 361 vs 351 classification is crucial for US developers. Products that meet the criteria for HCT/P under section 361 may not require the same extensive premarket approval as products falling under section 351, which are deemed more intensive in terms of oversight. This distinction significantly impacts both the clinical development trajectory and regulatory pathway management.

It is wise to familiarize your team with the FDA guidance documents regarding ATMPs to ensure alignment with regulatory expectations.

Step 4: Submission of the ATMP Application

Once the dossier is compiled and the necessary consultations with EMA or FDA have been conducted, the next step is the formal submission of the ATMP application. In the EU, the centralized marketing authorization application (MAA) for ATMPs must be submitted to the EMA, which screens for completeness before proceeding with scientific evaluation.

Ensuring completeness is key; the application will undergo an administrative review where missing elements can lead to delays. The EMA provides a timeline for the overall process, including the scientific evaluation of the application, which can take approximately 210 days. During this time, communication will be established with the applicant, enabling clarification requests that may be necessary for a thorough review. Preparing for potential questions and proactively addressing them can speed up this phase.

In the US, if the ATMP falls under the jurisdiction of the FDA as a biological product, it is critical to submit a Biologics License Application (BLA) for regulatory review. This similarly follows a structured approach which includes pre-approval inspections. Facilities should ensure compliance with FDA regulations regarding facility standards and procedures as outlined in 21 CFR Parts 210 and 211.

Step 5: Review Process and Market Access

After submitting the ATMP application, the review phase begins. The relevant regulatory authority conducts a thorough evaluation of the submitted data on quality, safety, and efficacy. For both EMA and FDA, this process encompasses the assessment of quality control measures, clinical trial designs, and outcomes.

For ATMPs, an additional layer of scrutiny may apply due to their intrinsic complexity and the innovative nature of the therapies. The committee may involve specialist reviewers with expertise in gene therapy, somatic cell products, or tissue engineering, facilitating a more nuanced evaluation. It is essential to prepare for potential requests for additional data or clarification during this evaluation period, often referred to as “day 120 questions” in the EMA submission process.

The outcome of the review may result in one of three decisions: approval, conditional approval, or rejection. A conditional approval may occasionally be granted, particularly in cases where there is unmet medical need and the potential for significant benefits outweighs the existing uncertainties regarding the product’s clinical efficacy.

Once approved, further steps regarding pricing, reimbursement, and post-approval commitments must be addressed. Companies must ensure compliance with continuing pharmacovigilance obligations, which includes monitoring adverse events and undertaking any post-marketing studies deemed necessary by regulatory authorities.

Step 6: Post-Market Surveillance and Compliance

Post-market surveillance is a critical aspect of maintaining the integrity and safety of an approved ATMP product. Following regulatory approval, companies are obligated to conduct ongoing monitoring and reporting of any adverse events related to their ATMPs. The specific requirements will vary by jurisdiction but may include:

• Periodic Safety Update Reports (PSURs): Required by EMA, these reports help to continuously evaluate the safety profile of the ATMP.
• Risk Management Plans (RMPs): These should be established to identify, assess, and mitigate risks surrounding the ATMP.
• Long-term follow-up studies: Essential for collecting data on the long-term safety and efficacy of the ATMP, especially for gene and cell therapies.

Regulatory authorities may also require ongoing communication regarding the response of the market, real-world evidence, and potential updates to the product label. As new data emerges, it is prudent for companies to maintain open lines of communication with the appropriate regulatory bodies to ensure compliance with evolving regulations.

Engaging an EMA ATMP regulatory consulting expert can provide significant advantages during the initial stages of product development through post-market activities, thereby ensuring adherence to all regulatory pathways.

In conclusion, understanding the complete lifecycle of ATMPs from classification to post-market obligations is vital for regulatory success. Each step requires careful attention to detail, harmonization across various document types, and proactive engagement with regulatory authorities. By maintaining rigorous standards and transparent practices, companies can ensure the successful development and commercialization of advanced therapy medicinal products.